share_log
Reuters ·  May 8 07:25
Seres Therapeutics Inc - Ser-155 Phase 1B Placebo-Controlled Cohort 2 Clinical Readout Expected End of Q3 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment